Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02785744 · ClinicalTrials.gov registry record
Genzyme Osteopenia/Osteoporosis Study
A clinical trial, sponsored by NYU Langone Health.
- Completed
- Registry status
- 76
- Enrollment target
NCT02785744 is a clinical trial that has completed, run by NYU Langone Health. The registered enrollment target is 76 participants.
The verdict
NCT02785744 has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- 76 participants
- Enrollment target
Study Summary
Gaucher disease is a most common genetic metabolic disease characterized by low platelet number, liver and spleen enlargement and various forms of bone diseases including low bone mineral density leading to brittle bones. Various treatment options are now available for this disease. The purpose of this research study is to determine the prevalence of Gaucher disease in patients with low bone mineral density as observed by DEXA scan, which is a form of X-Ray of the bone.
Interventions
- OTHER Gaucher disease DNA mutation analysis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2016-04-01 |
| Est. Completion | 2019-09-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02785744
The ClinicalTrials.gov registry entry for NCT02785744 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Gaucher disease DNA mutation analysis is the first listed.
NCT02785744 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02785744 about?
NCT02785744 is a clinical study titled "Genzyme Osteopenia/Osteoporosis Study". Gaucher disease is a most common genetic metabolic disease characterized by low platelet number, liver and spleen enlargement and various forms of bone diseases including low bone mineral density leading to brittle bones. Various treatment options are now available for this disease. The purpose of ...
What is the current status of trial NCT02785744?
This trial is currently completed. The enrollment target is 76 participants. The study started on 2016-04-01. Estimated completion is 2019-09-01.
What interventions are being tested in trial NCT02785744?
The interventions under investigation include: Gaucher disease DNA mutation analysis (OTHER).
Who is sponsoring clinical trial NCT02785744?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.